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Abstract Receptor activator of nuclear factor kappa B
ligand (RANKL) and its natural antagonist, osteoprotegerin
(OPG), are, respectively, an indispensable factor and a
potent inhibitor for osteoclast differentiation, activity, and
survival. The development of a human monoclonal anti-
body to RANKL, denosumab, constitutes a novel approach
to prevent fragility fractures in osteoporosis, skeletal
complications of malignancy, and potentially bone erosions
in rheumatoid arthritis (RA). In addition to being expressed
by osteoblasts, RANKL is abundantly produced by activat-
ed T cells, and synoviocytes in RA, whereas its receptor,
RANK, is also expressed by monocytes/macrophages and
dendritic cells. However, in preclinical and clinical studies
of RA—including patients with some degree of immuno-
suppression—RANKL inhibitors did not significantly alter
inflammatory processes. RANKL, RANK, and OPG defi-
ciency in murine models highlights the important role of
this pathway in the development and maturation of the
immune system in rodents, including functions of T and/or
B cells, whereas OPG overexpression in mice and rats
seems innocuous with regard to immunity. In contrast, loss-
of-function mutations in humans have more limited effects
on immune cells. In clinical studies, the overall rate of
infections, cancer, and death was similar with denosumab
and placebo. Nevertheless, the risk of severe infections and
cancer in some specific tissues remains to be carefully
scrutinized.
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Introduction
Local and systemic bone loss (osteoporosis) that occurs in
inflammatory diseases and gonadal steroid deficiency,
subchondral bone erosion in rheumatoid arthritis (RA), as
well as osteolytic bone metastasis, are all caused by the
bone-resorbing effects of osteoclasts. Two factors secreted
primarily by bone marrow stromal cells and osteoblasts are
necessary and sufficient to induce differentiation of hema-
topoietic precursors common to the monocyte/macrophage
and osteoclast lineages into multinucleated, bone-resorbing
cells: colony-stimulating factor-1 (CSF-1 or M-CSF) and
the tumor necrosis factor (TNF)-related cytokine receptor
activator of nuclear factor kappa B ligand (RANKL) [1, 2].
By engaging specific adaptor molecules, such as the TNF
receptor-associated factor TRAF6 and the Grb-2-associated
binder-2 Gab2, RANKL binding to its receptor RANK
further promotes activation and survival of mature osteo-
clasts [3–5]. In both mice and humans, deleting or
inactivating mutations of RANKL and RANK genes results
in the absence of osteoclasts and osteopetrosis [6–9].
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Osteoblasts/stromal cells also produce osteoprotegerin
(OPG), a decoy receptor which binds RANKL, thus
preventing its own binding to RANK. Thereby, OPG exerts
a negative regulation on osteoclastogenesis, promotes
apoptosis of mature osteoclasts, and ultimately inhibits
bone resorption [10]. Hence, OPG-deficient mice exhibit
increased bone turnover, a reduction in cortical and
trabecular bone volume, and they develop spontaneous
fractures [11]. In contrast, overexpression of OPG or
RANK-Fc (that functions as a RANKL inhibitor) in
transgenic rodents causes high bone mass, but without the
typical features of osteopetrosis, as in these models, bone
mass correlates with the level of OPG or RANK-Fc
expression [10, 12, 13]. Hence, the discovery of the
RANKL/RANK/OPG pathway has led first to the develop-
ment of recombinant OPG (rhOPG) and OPG-Fc, then to
that of a fully human IgG2 monoclonal antibody to
RANKL named denosumab, as a novel therapeutic agent
for potential application in osteoporosis [14, 15], RA [16],
and cancer [17].
Besides being produced by osteoblasts, RANKL is also
abundantly expressed by activated CD4+ T cells, whereas
mature B cells express OPG [18, 19]. Many cytokines
produced by monocytes and/or T cells have actually been
identified as stimulators of bone resorption, including
interleukin (IL)-1, IL-4, IL-6, IL-7, IL-15, IL-17, interferon
(IFN)-γ, and TNF-α [20–28]. Hence, T lymphocytes are
key to the process of local and systemic bone loss
associated with inflammation, autoimmune diseases, and
graft rejection [29, 30] and also play a role in bone loss due
to estrogen deprivation [31]. The point is that RANKL-
producing T cells not only contribute to osteoclast
activation [18, 19] but also to the co-stimulation of other
RANK-expressing cells, such as dendritic cells (DC) and
monocytes/macrophages [32, 33] (Fig. 1).
In addition to inhibiting osteoclastogenesis, RANKL
inhibitors could therefore potentially modulate and/or
inhibit an array of T-cell-mediated reactions, which has
raised some concerns about their specificity and safety. This
review focuses on the experimental evidence as to the role
of the RANKL/RANK pathway and its inhibitors on
inflammation and immunity.
Effects of RANKL inhibitors on inflammatory diseases
Comparing and contrasting the effects of RANKL and TNF
inhibitors
Administration of agents blocking TNF-α or IL-6 in both
animal disease models and humans has proven efficient in
controlling inflammatory processes characteristic of RA
[34–37] and other autoimmune diseases [38, 39]. Treatment
of RA with TNF-specific antagonists, such as etanercept,
infliximab, and adalimumab, also prevents subchondral
erosions and cartilage destruction [35, 40–42], whereas
their effects on the preservation of systemic bone mass
seem limited when withdrawal of corticosteroids is taken
into consideration [41, 43, 44]. Treatment of patients
suffering from RA or other inflammatory disorders by
biological agents that target members of the TNF family
has shown an increase in the number of infections and
hematologic malignancies (Table 1) [45–47]. Admittedly,
TNF inhibitors significantly increase the risk of contracting
tuberculosis and of its reactivation [45, 48]. Several
investigators demonstrated that transmembrane TNF-α
(TmTNF) plays an important role in the inflammatory
response to infection, as TmTNF contributes to the
induction and regulation of Th1-type cytokines and chemo-
kine expression which is crucial for the development of
bactericidal granulomas and resistance to mycobacterium
infections [49, 50]. Moreover, TNF-α also appears to fulfill
an important regulatory function in controlling repair and
regenerative processes after tissue damage [51].
Similar to TNF, RANKL is abundantly produced by
infiltrating T cells and synoviocytes in RA [7, 52–54]. In
contrast to TNF inhibitors, however, OPG administration in
animal models of RA, such as the rat model of adjuvant-
induced arthritis and TNF-α transgenic (Tg) mice—which
spontaneously develop arthritis—did not alter the severity
of joint inflammation, despite a marked reduction of
periarticular bone erosions, as well as of cortical and
trabecular bone loss at distant skeletal sites [7, 55]. Even
RANKL−/− mice remained susceptible to arthritis induced
by serum transfer [55]. Recently, Stolina et al. compared the
effects of the RANKL inhibitor OPG-Fc, the TNF-α
inhibitor pegsunercept, and the IL-1 inhibitor anakinra on
rats with established adjuvant- or collagen-induced arthritis
[56]. Parameters of local and systemic inflammation (paw
swelling and serum levels of pro-inflammatory cytokines)
were dramatically decreased by anti-TNF-α or anti-IL-1
therapy, while local, but not systemic, bone loss was
partially reduced. In contrast, OPG-Fc therapy inhibited
local and systemic bone loss in both arthritis models
without modifying local or systemic inflammation.
In a phase II clinical trial, administration of 60 or
180 mg s.c. of denosumab every 6 months to patients with
active RA (and receiving methotrexate) halted the progres-
sion of subchondral bone erosions and systemic bone loss,
although without an apparent reduction of clinical inflam-
mation and joint space narrowing [7, 16, 55, 57].
Altogether, these observations suggest that—contrary to
anti-TNFs—RANKL and its inhibitors do not play a major
part in T-cell-mediated inflammatory processes in RA,
which could be accounted for by the redundant effects of an
array of pro-inflammatory cytokines [58]. Moreover, in the
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above clinical trial, the rate of adverse events and serious
infections requiring hospitalization did not differ between
patients treated with denosumab and those with placebo,
although the episodes of influenza (self-reported), upper
respiratory tract, and urinary tract infections were numer-
ically higher in the denosumab group. Hence, in a recent
survey, rheumatology experts raised some concerns that the
risk of infection with RANKL inhibitors could be worsened
if employed concomitantly to anti-TNFs and/or other
biological agents [59].
Inflammatory bowel diseases
In the CD4+ CD45RBHi T-cell transfer mouse model of
inflammatory bowel disease (IBD), the effects of OPG-Fc
administration were similar to those in RA: While dramat-
ically improving bone density, OPG-Fc did not modify
inflammatory parameters nor reduce infiltration of the
gastrointestinal tract by inflammatory cells (colitis) [60].
In contrast, in IL-2-deficient mice—that spontaneously
develop an autoimmune disease characterized by hyper-
activation of CD4+ T cells with multi-organ inflammation
and massive T-cell infiltration of the gastrointestinal tract—
administration of OPG-Fc not only led to a significant
increase in bone density but also improved gastrointestinal
tissue architecture [61]. In this particular model, by
antagonizing RANKL expressed by T cells, it is possible
that OPG-Fc interrupted the amplification loop of T-cell
activation and infiltration in colonic tissues mediated by
DCs (Fig. 2). Hence, in models where major immunolog-
ically active molecules are deleted (e.g., IL-2 KO and
CD40 KO [62]), RANK/RANKL signaling may become
the main co-stimulatory pathway for crosstalk between T
and B cells and DCs [32, 62, 63].
Whether these models are of clinical relevance however
remains uncertain, and it is therefore hardly surprising that
in most circumstances, RANKL inhibitors did not alter
tissular inflammation.
Effects of RANKL/RANK/OPG
on T- and B-cell-mediated immunity
Effects on the immune system organogenesis and T cells
While innate immune responses induced by inflammation
represent a physiological (and sometimes pathophysiolog-
ical), non-specific reaction to pathogens (and self-antigens)
Fig. 1 RANKL-mediated crosstalk between immune cells and
osteoclasts. RANK ligand is an essential mediator of osteoclast
formation, function, and survival and is produced not only by bone
marrow stromal cells and osteoblasts but also by T cells. RANKL
binds to the RANK receptor, which is expressed by monocytes/
macrophages (Mo/Mø) and osteoclast precursors, dendritic cells
(DCs)/antigen-presenting cells (APC), and T cells. The RANKL
antagonist and TRAIL-binding factor OPG is expressed by mature
osteoblasts and B cells (as well as by other cell types not shown here)
and inhibit RANKL-induced osteoclastogenesis
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and lack memory, the adaptive immune response is
characterized by a high degree of specificity and memory,
involving specialized and highly differentiated cells. A
prerequisite of specific innate and adaptive immune
responses is the stepwise maturation of T and B lympho-
cytes, and there are distinct stages in the development of
lymph node (LN) organogenesis that require the specific
expression of adhesion molecules, cytokines, and chemo-
kines. LN, Peyer's patches, and nasal-associated lymphoid
tissue (NALT) seem to follow a common developmental
program, whereas spleen organogenesis undergoes an even
more complex process.
Studies in mice have mapped numerous genes essential
for lymphoid tissue development [64], including members
of the TNF family such as surface lymphotoxin LTα1β2
and RANKL. LTα1β2 signals through the lymphotoxin β
receptor (LTβR), and mice deficient in LTα, LTβ, or LTβR
lack LN [65–67]. Similarly, in the absence of RANKL,
RANK, or TRAF-6, LN cannot develop, whereas the
formation of Peyer's patches, NALT, and splenic micro-
architecture is not affected [6, 18, 68, 69]. In RANKL-
deficient mice, impaired LN development results from a
defect in colonization and cluster formation of hemato-
lymphoid precursor cells [68], particularly α4β7+ CD4+
CD3− T cells. Thymus size and cellularity of these mice are
diminished, indicating that RANKL further contributes to
early thymocyte development [18]. Although the total
number of T lymphocytes as well as their production of
IFN-γ and IL-2 is lower in RANKL−/− mice, they do
proliferate adequately, and the subsets of CD4+ and CD8+ T
cells occur in normal amounts, probably owing to redun-
dant co-stimulatory pathways (such as CD40-CD40L and
CD28-CD80/86), indicating that thymus function remains
unaffected. Intriguingly, RANK−/− mice boast normal
thymic development, a normal percentage of thymocytes
and T-cell precursors [6]. Consequently, as suggested by
Table 1 Properties of anti-tumor necrosis factor and anti-RANKL antibodies in humans
Description Anti-TNF Anti-RANKL
Drug structure Soluble TNFRII-human Fc fusion protein (etanercept) Human monoclonal IgG2 antibody (denosumab)
Potential indications Rheumatoid arthritis Osteoporosis
Juvenile chronic arthritis Skeletal complications of malignancy
Psoriatic arthritis
Ankylosing spondylitis Rheumatoid arthritis
Psoriasis
Effect on T cells Induces apoptosis NA
Increases Treg
Effect on B cells No direct effect NA
Effect on mono-mϕ Induces apoptosis NA
Decreases production of inflammatory cytokines
Adverse events
Infectious Tuberculosis Cellulitis/erysipelasa
Bacterial infections Diverticulitisa
Intracellular pathogens
Upper respiratory tract
Tumoral Lymphoma, mostly non-Hodgkin's Breast?b
Reproductive (ovary)?b
Gastrointestinal?b
Others Dermatitis and Eczemac
Hypersensitivity?
Auto-antibodies Very frequent: ANA, anti-dsDNA, anti-cardiolipin,
but their formation is not associated with specific
clinical syndrome
None
Concerning RANKL antagonist effects on immune cells in animals and in vitro, see text
NA data not available in humans
a In the post-menopausal osteoporosis and HALT trials combined
b In the post-menopausal osteoporosis trials only. The “?” indicates that the significance of these observations is still unclear (according to the FDA advisory
committee for reproductive health drugs, August 2009)
c In the post-menopausal osteoporosis trials
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these authors, RANKL signaling in the thymus might also
be mediated through a receptor other than RANK [6].
Contrasting with RANKL- and RANK-deficient mice,
highly expressing OPG-transgenic (OPG-Tg) mice pres-
ent no alterations of LN, thymus, or spleen [70]. OPG-Tg
rats present normal LN development at gestational day 11
when OPG levels are already high [70], suggesting that
even residual effects of RANKL may be sufficient in this
regard. Similarly, the administration of RANKL-Fc in
mice did not affect cytokine production and proliferation
of T cells, nor did it modify T-lymphocyte infiltration of
inflammatory tissues [71]. Moreover, when OPG or
RANKL are added to wild-type murine T-cell cultures,
their proliferation and production of cytokines remain
unaffected, suggesting that RANKL signaling is not
crucial for mature T-cell functions [18].
Finally, patients with mutations in the TNFSF11
(RANKL) gene or in the TNFRSF11A (RANK) gene have
normal lymphocyte counts of the peripheral blood and do
not present major abnormalities in T-cell phenotypic and
functional properties [8, 9].
Effects on B cells
RANKL−/− mice exhibit a marked alteration of B-cell
development with defective transition of pro-B to pre-B and
reduced numbers of B cells in the spleen [18]. In RANK−/−
mice, the developmental defect in the B-cell lineage is
massive with a decrease in mature B cells in the bone
marrow and peripherally [6]. In three out of the eight
patients with osteoclast-poor osteopetrosis due to mutations
in the TNFRSF11A (RANK) gene, the number of mature B
cells was significantly decreased, and their serum immu-
noglobulin levels (particularly IgG) were low. Moreover,
two of these patients failed to produce antibodies to tetanus
toxoid vaccination [9]. Of note, their Ig level—although
reduced—was not as low as that observed in patients with
common variable immune deficiency. Furthermore, the
reasons for the hypogammaglobulinemia in patients with
mutations in the TNFRSF11A (RANK) gene may be as
follows: (1) in response to RANKL, osteoclasts are unable
to produce high levels of APRIL, a player of B-cell
activation and isotype switching, and (2) the marked
osteopetrosis limits anatomic niches for B-cell development
and survival in bone marrow [72]. In addition, patients with
osteoclast-poor osteopetrosis due to mutations in the
TNFSF11 (RANKL) gene affecting its cell surface presen-
tation were not reported to suffer from immunological
deficiencies nor to be particularly prone to infection [8]. To
explain the discordant observations concerning B-cell
functions in these patients with RANKL and RANK
mutations, it has been hypothesized that the mutant
RANKL protein might still retain some selective activity
on immune cells [8] which, to our knowledge, has not yet
been substantiated.
In OPG−/− mice, proliferation of pro-B cells is increased,
but there is a deficit in antibody response to antigen due to
an alteration in the isotype switch of IgGs, suggesting that
OPG is essential for B-cell maturation and development
through its inhibitory effect on TRAIL [73, 74]. In contrast,
OPG-Tg mice and rats present neither a defect in B-cell
development and maturation nor impaired humoral re-
sponse to immune challenges [70], confirming that these
rodents are immunocompetent. In addition, in mice treated
with OPG-Fc and injected with a pneumovax vaccine,
production of IgM and IgG subtypes was identical to that of
mice injected with control-Fc (Table 2) [75]. Moreover,
administration of denosumab to adult ovariectomized
cynomolgus monkeys over a period of 15 months had no
apparent effect on basal immune parameters and did not
elicit any effect on T, B, or NK cells at any time point [76].
In summary, mouse genetic models clearly indicate that
the RANKL/RANK/OPG pathway is essential to the
development of lymphoid organs and T and B cells,
whereas experiments of nature in humans show that loss-
of-function mutations in this system have only moderate
and selective effects on B-cell immunity. On another side,
overexpression of OPG even from the embryonic stage, as
well as administration of RANKL antagonists, do not
appear to impair the development and/or activation of T and
B cells (Table 3). These results also suggest that RANKL
inhibitors do not impair autoimmunity, since autoimmune
diseases and some allergic diseases are partly due to a
defect in IgG switching [77, 78].
Fig. 2 Role of RANKL/RANK signaling on co-stimulation of innate
immune cells. Interaction between T lymphocytes and DC as well as
their activation occur (1) through the T-cell receptor (TCR)-HLA
complex and (2) through co-stimulatory complexes such as CD28/B7
or CD40L/CD40 molecules. RANKL interaction with RANK pro-
motes DC survival [62] and enhances monocyte functions [33]. This
interaction is similar to that of the co-stimulatory CD40L/CD40
interaction [98]. CD40L is rapidly expressed by activated T cells,
whereas RANKL expression occurs within 48 h. Consequently,
CD40L/CD40 interaction is key to controlling the priming stage,
whereas RANKL/RANK interaction may take place later and is of a
more accessory nature [99]
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Effects of RANKL/RANK/OPG on other immune cells
Immune cells need to interact with each other in order to
initiate an innate and adaptive immune response and to
produce pro- and anti-inflammatory cytokines, chemokines,
and antibodies to pathogens. DCs and monocyte/macro-
phages are key components of the innate immune response
and are major antigen-presenting cells (APC) priming T
cells to proliferate and initiate an adaptive immune response
[79]. In turn, activation and proliferation of T cells control
antigen dispersion and, due to the secretion of cytokines,
trigger a feedback amplification loop that further enhances
functions of DC and monocyte/macrophages, as well as B-
cell proliferation and antibody production in order to
control the dissemination of antigens.
Effects on monocyte–macrophages
Monocyte–macrophages are closely related to osteoclasts
and express RANK on their cell surface. Monocytes from
peripheral blood as well as monocytic cell lines both
differentiate into osteoclasts when cultured with M-CSF
and RANKL [1]. Stimulation of monocytes with RANKL
induces the expression of Bcl-xl, pro-inflammatory cyto-
kines such as IL-1β and TNF-α, chemokines, co-
stimulatory molecules (CD80 and CD86), and MHC-II on
Table 3 Evaluation of RANKL inhibition on immune parameters in preclinical models
Length of RANKL inhibition
Short-term
(<3 weeks, OPG-
or RANK-Fc)
Long-term
(>1 year, dmab)
Life-long
(OPG-Tg)
Baseline immune profile Cellular composition of blood [70] Cyno Mouse, rat
Systemic cytokine levels [70] Mouse, rat
Systemic immunoglobulin levels [70, 75] Mouse Mouse, rat
T and B cell proliferation in vitro to specific
antigens [70, 75]
Mouse Mouse, rat
Immune challenge Delayed contact hypersensitivity to oxazolone
in skin [70, 75]
Mouse Mouse
Innate response to LPS [70] Mouse, rat
T-cell-dependent immune response to KLH
[70, 75]
Mouse Cyno Mouse
T-cell-independent immune response
to Pneumovax [70, 75]
Muse Mouse
Infectious disease BCG bacterial infection [70] Mouse
Influenza viral infection [97] Mouse
Autoimmune disease Immune-mediated arthritis [56] Rat
Inflammatory bowel disease [60] Mouse
Table 2 Comparative phenotypes of RANK−/−, RANKL−/−, and OPG−/− mice
RANK−/− mice RANKL−/− mice OPG−/− mice
Bone Osteopetrotic; no osteoclast present Osteopetrotic; no osteoclast present Osteoporotic; osteoclast activation
Thymus Normal size; thymocyte dvp normal Reduced size; thymocyte dvp impaired Normal size
LN LN agenesis; Peyer's patches smaller LN agenesis; Peyer's patches smaller Normal LN dvp; Peyer's patches
normal
Spleen Normal; extramedullary hematopoiesis Normal; extramedullary hematopoiesis Normal
LT Normal T-cell dvp; CD4/CD8 ratio N Deficit in early intrathymic T-cell dvp Normal T-cell dvp; CD4/CD8 ratio N
CD4/CD8 ratio N
LB B-cell dvp ND; reduced number of B-cells B-cell dvp impaired; reduced number
of B-cells
Increased number of B-cells; altered
Ig isotype switching
DC Normal dvp and function/activation Normal dvp and function/activation Increased survival and function/activation
Adapted from Dougall et al. [6]
LN lymph nodes, dvp development, LB lymphocytes B, LT lymphocytes T; Ig immunoglobulin, DC dendritic cells, ND not determined
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their cell surfaces, which protects these cells from apopto-
sis, increases their phagocytic properties, and activates
antigen presentation [33]. However, in studies on
RANKL−/− mice, both the number and distribution of
monocyte–macrophages were normal [18]. Differentiation
and function of monocyte–macrophages were also pre-
served in RANK−/− mice, demonstrating that contrary to
osteoclastogenesis, the RANKL/RANK pathway is not
crucial to macrophage development [6]. However, the role
of RANKL/RANK in monocyte–macrophage functions
becomes more prominent when other essential co-
stimulatory molecules are missing, such as in mice lacking
CD40L [80], a T-cell surface protein that is essential for
activation of monocyte–macrophages and a close relative
to RANKL [32, 81]. Whether RANKL antagonists would
similarly worsen the deficient monocyte–macrophage
functions in patients with the hyper-immunoglobulin M
syndrome due to CD40 mutation or with CD40L deficien-
cy is currently unknown.
Most important in terms of the pharmacological effects
of denosumab on both immunity and control of infection,
blockade of RANKL function in vivo by RANK-Fc did not
alter the functions of monocytes, nor did it amplify
inflammatory processes in mice models of lipopolysaccha-
ride (LPS)–endotoxic shock and inflammatory arthritis
[33]. LPS is a component of cell walls of Gram-negative
bacteria and a potent activator of monocyte/macrophage
function due to its interaction with CD14 and toll-like
receptor 4 (TLR4). LPS activation of monocyte/macro-
phages also induces co-stimulatory proteins such as CD40,
CD80, and CD86, which in turn activate T cells. Therefore,
even if the RANKL/RANK pathway is inhibited, redun-
dancy of activating pathways and immune cell interactions
will sustain the immune response to pathogens. As further
proof of this concept, OPG administration to mice infected
with Mycobacterium bovis did not alter their immune
response [75].
Effects on antigen-presenting cells (APC)
APC play an essential role in the presentation of foreign
peptides or altered self-peptides to T lymphocytes and thus
in the induction of antigen-specific T-cell activation. APC
are mainly composed of DCs and Langerhans cells (LC), a
subset of DCs found in the skin epithelium and in mucosae.
T cells that express RANKL play an agonistic role on DC
activation in vitro due to co-stimulatory processes involving
CD40L/CD40 interaction (see above) [32]. Hence, RANKL
enhances DC survival, antigen presentation [62, 63], and
production of cytokines [82]. Accordingly, in OPG−/− mice,
due to the increased survival of DCs, the DC–T-cell
interaction may be prolonged and T-cell proliferation more
pronounced [73]. However, in RANKL−/− mice and
RANK−/− mice, DC development and function are intact,
with normal expression of DC surface markers and co-
stimulatory markers, and the appropriate stimulation of
alloreactive T cells [6, 18]. Phenotypic and functional
analyses of DCs in subjects with either TNFSF11 (RANKL)
or TNFRSF11A (RANK) gene mutations also did not reveal
any major abnormalities [8, 9]. Thus, although RANKL
appears to be an effective co-stimulatory factor, it is not
essential for DC activation.
Like DCs, LCs also express RANK, and LC
proliferation and survival is impaired in RANKL−/−
mice [83, 84]. Ultraviolet exposure or inflammation
upregulated the expression of RANKL by inflamed
keratinocytes leading to an increase of regulatory
CD4+ CD25+ T cells [83], which in turn helps to control
cutaneous inflammation and hyperallergic responses.
Loser et al. [83] demonstrated that in transgenic mice
expressing RANKL under the transcriptional control of
the keratin-14 (K14) promoter (K14-RANKL Tg mice),
the number of regulatory CD4+ CD25+ T cells was
increased by activation of DCs, and contact hypersensi-
tivity responses were decreased.
Effects of RANKL inhibition on immune surveillance
of cancer
Both innate and adaptive immune mechanisms are
implicated in the surveillance of cancer. Thus, antigen-
presenting DCs, CD8 cytotoxic T lymphocytes, and
CD4 T helper cells and, more specifically, natural killer
(NK), regulatory T cells (Treg), and Tγδ cells interact in
controlling and eventually eliminating tumor cells. A
large number of cytokines and chemokines have been
implicated in the immune response to cancer, since they
amplify the inflammatory reaction—as in the case of IL-
2—and/or cause lysis (by apoptosis) of tumor cells—as
in the case of IFN-γ. It follows that although it is not
essential, the immunomodulatory effect of RANK sig-
naling on the various effectors of this system described
above could affect immune surveillance of cancer.
CD4+ T cells in particular can generate direct cytotoxicity
via TRAIL. When added together with TRAIL to
osteoblast-like cell cultures, OPG prevents TRAIL-
induced apoptosis [85]. OPG secreted by prostate cancer
cells may also protect them from TRAIL-induced apopto-
sis [86]. Therefore, the binding of OPG to TRAIL and
interference with the natural defense mechanism against
tumorigenesis is a potential concern related to OPG
treatment. In this regard, denosumab has the advantage
over OPG in that it does not bind to TRAIL [87]. On the
other hand, inhibiting the excess RANKL commonly
produced in bone infiltrated by tumor cells interrupts the
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vicious circle of bone lysis stimulation of metastatic
growth, which can prevent the skeletal progression of
cancer, at least in preclinical models [88].
Risk of infection and cancer associated with denosumab
in clinical trials
In a combined cohort of more than 8,000 post-menopausal
women with osteoporosis from fracture (FREEDOM) and
bone loss prevention [89, 90], the incidence of serious
adverse events was similar in the denosumab and placebo
(PBO) groups (25.3% and 24.3%, respectively), but deno-
sumab tended to decrease the risk of death (HR, 0.76; CI,
0.55–1.03; p=0.08). In a combined cohort of about 1,700
subjects with non-metastatic breast cancer, i.e., including
patients who faced a higher risk of infections and death, the
incidence of serious adverse events and death was also
similar in denosumab and PBO groups (31.6% vs 27.6% and
5.2% vs 5.6%, respectively) [91, 92]. Combining the results
of these four studies (∼10,000 subjects), infections were
reported in 50.6% of subjects in the PBO group and 50.1%
in the denosumab group, while serious infections were found
in 4.3% and 3.4% of subjects treated with denosumab and
PBO, respectively (NS). Sepsis (≤0.2%) and opportunistic
infections (≤2%) including tuberculosis and fungal infections
were rare, and their incidence was similar in the two groups.
Severe pneumonia (1%), bronchitis (0.2%), and urinary tract
infections (0.3%) also occurred in similar proportions in the
two groups, while rare cases of severe skin infections
(mostly at lower extremities) and diverticulitis were
observed more frequently with denosumab than with
PBO (erysipelas/cellulitis, 0.2% PBO, 0.4% denosumab;
diverticulitis, 0.1% PBO, 0.3% denosumab). Considering
the role of RANKL/RANK in the modulation of the
immune/inflammatory responses in the skin (see above)
and the small but significantly higher number of patients
with eczema among post-menopausal women treated with
denosumab as compared to placebo (FREEDOM), we
suggest that RANKL inhibitors could amplify cutaneous
allergic and inflammatory responses rather than increase
susceptibility to infection itself. A recent meta-analysis
including the FREEDOM trial and using a model of
fixed rather than random effects revealed a significantly
higher risk of serious infections in women with
osteoporosis or osteopenia treated with denosumab than
in controls (RR=1.26, CI=1.01–1.57, p=0.04). When
patients with non-metastatic breast cancer (HALT trial)
were excluded, the risk increase was of borderline
significance (RR=1.25, CI=1.00–1.59; p=0.05).
The overall incidence of cancer in post-menopausal
women from the FREEDOM trial and the bone loss
prevention trial did not differ between denosumab (4.8%)
and placebo (4.2%), nor did the number of malignancy-
related deaths in both the FREEDOM and HALT prostate
cancer [91] trials together (denosumab n=26, PBO n=35).
In the combined sample of 8,091 post-menopausal
women, there were no differences between denosumab
and PBO in the number of skin, lung/mediastinum, or
hematopoietic neoplasms including lymphomas, whereas
the denosumab group showed a greater number of cases of
breast cancer (35 vs 28 in PBO), cancer of the reproduc-
tive organs (21 vs 9 in PBO, mostly the ovaries), and of
the GI tract (35 vs 24 in PBO). The latter was observed
more specifically in the colon, pancreas, and stomach.
With regard to the incidence of breast cancer in the two
groups, there were only five more cases during year 3 in
the group of nearly 4,000 women receiving denosumab
than in those receiving PBO. It should also be noted that in
the cancer trials (breast and other) involving thousands of
patients treated monthly with double-dose (120 mg)
denosumab for the prevention of skeletal-related events,
overall disease progression and survival did not differ
between denosumab and the comparator group (zoledronic
acid) [93, 94].
Summary and perspective
RANKL, RANK, and OPG are not only expressed by bone
cells but also by T cells, B cells, DCs, and monocyte–
macrophages amongst others. Absence of RANKL or
RANK during embryogenesis in mice results in thymus
and LN defects, but this phenomenon has not been reported
in humans with mutations in these genes. Hence, mutations
in the TNFSF11 (RANKL) gene do not cause severe
immune deficiencies nor have they been reported to result
in an increased risk of infection, cancer, or immune
disorders [8]. Nevertheless, mutations in the TNFRSF11A
(RANK) gene may cause hypogammaglobulinemia in some
patients, with a potentially increased risk of infection [9].
As underscored by Sobacchi et al. [8] “the contrast in the
effects of mutations in the RANKL/RANK/OPG system
between the knockout mouse phenotype and the human
phenotype could be due to species-specific differences.”
Blocking the RANKL/RANK pathway in adult rodents
and monkeys apparently does not lead to major immune
cell dysfunctions, in contrast to TNF-α or IL-1 inhibitors.
As a corollary of its apparent lack of major effects on the
immune system, RANKL inhibition does not prevent
inflammation driven by T cells in RA or IBD. Inhibition
by denosumab of RANKL binding to RANK has proven
effective in preventing bone resorption and/or fractures and,
to be generally safe, in patients with osteoporosis, RA, and
non-metastatic (prostate and breast) cancer [16, 89, 91, 92].
Whether inhibition of T cell-mediated, RANKL-dependent
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activation of DCs and monocyte–macrophages would affect
the capacity to generate and/or control immune reactions
(primarily to infection and cancer) in some tissues, like in
the skin and colon, however, remains to be scrutinized as a
large number of possibly older and thereby more immuno-
compromised patients might be treated with denosumab in
the future. On another side, RANK signaling also plays a
role in the development of breast tissue [95], as well as in
angiogenesis and endothelial permeability [96], which
could be modified by RANKL inhibitors.
As denosumab progresses from investigation to clinical
application, and as biological agents targeting cytokines are
becoming more common in clinical practice, the efficacy and
safety of association of biological agents, such as anti-TNF
and denosumab for treatment of RA and other inflammatory
diseases, will also need to be specifically investigated.
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